Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | MMP3 | P08254 | 5/20 | 0.49 |
| ▸ | MMP1 | P03956 | 4/20 | 0.49 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | MMP7 | P09237 | 4/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.49 |
| ▸ | MMP13 | P45452 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803901 | 0.94 | PTGS2 (0.68) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL30069983 | 0.84 | PTGS2 (0.55) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL8652231 | 0.84 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL8974143 | 0.84 | PTGS2 (0.63) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL5458774 | 0.82 | PTGS2 (0.57) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL10951291 | 0.82 | PTGS2 (0.57) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL689244 | 0.82 | ADAMTS4 (0.55) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL7677302 | 0.82 | PTGS2 (0.62) | PTGS2CA12CA2CA9KIF11 | |
| SCHEMBL10300269 | 0.82 | PTGS2 (0.62) | PTGS2CA12CA2CA9KIF11 | |
| SCHEMBL8384830 | 0.81 | PTGS2 (0.68) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-1987004-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | PTGS2 48/4885CA12 3110/4885CA1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.